James F. Howard Jr., MD

Target selection in MG increasingly depends on understanding where a therapy acts within the autoimmune pathway and which patient factors favor that approach. Supported by Vor Bio Medical Affairs.

Managing MG begins with balancing rapid disease control against the cumulative burden of corticosteroids and other long-term immunosuppressive therapies. Supported by Vor Bio Medical Affairs.

Effective MG care requires treatment goals that reflect not only disease activity but also each patient's priorities, responsibilities, and expectations. Supported by Vor Bio Medical Affairs.

Decades of MG biology are now informing increasingly precise strategies that intervene at different points along the autoimmune pathway. Supported by Vor Bio Medical Affairs.

Disease severity is only part of the picture in MG, as functional demands, comorbidities, and everyday limitations can directly shape treatment urgency. Supported by Vor Bio Medical Affairs.

Accurate MG diagnosis begins with recognizing fluctuating, fatigable weakness and knowing when clinical or serologic findings point elsewhere. Supported by Vor Bio Medical Affairs.

Expert neurologists share approaches to switching MG treatment due to either poor disease control or adverse events.

Experts in neurology review the varied routes of administration of targeted treatment in MG, highlighting intravenous and subcutaneous formulations and how they can provide more patient-centric care.

Expert neurologists discuss the treatment algorithm of MG, focusing on the use of targeted therapies as well as barriers to their use.

James F. Howard Jr, MD, shares thoughts on the future of the treatment of gMG, highlighting the renewed interest in the disease landscape.

An expert neurologist reviews efficacy and safety data of rozanolixizumab, an FcRn-targeting agent approved for treatment of gMG, as well as how it differs from efgartigimod.

James F. Howard Jr, MD, discusses both intravenous and subcutaneous efgartigimod for the treatment of gMG.

An expert neurologist comments on the need for generalized myasthenia gravis treatment to be tailored to the patient to alleviate symptoms without significant adverse effects.

An expert reviews targeted therapies in generalized myasthenia gravis, highlighting complement and neonatal Fc receptors.

An expert comments on the impact of factors such as disease course, antibody status, and patient adherence on the management of gMG.

A physician expert discusses the socioeconomic burden of gMG on both the patient and the caregiver.

James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN, deliver parting thoughts on the state of the myasthenia gravis treatment, focusing on current deficits and future prospects.

Two subject matter experts discuss promising treatment methods and agents in the pipeline for patients with myasthenia gravis.

James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN, discuss the efficacy and safety of FcRn inhibitors, as well as consider their role in the rapidly evolving treatment landscape.

Experts discuss the benefits of complement inhibitors in reducing symptoms of myasthenia gravis.

James F. Howard Jr., MD, and Nicholas J. Silvestri MD, FAAN, review the role of complement inhibitors and FcRn inhibitors in the management of myasthenia gravis.

Thought leaders review the role of non-pharmacological strategies to manage myasthenia gravis comorbidities.

A comprehensive review of drugs to avoid when designing treatment plans for patients with myasthenia gravis.

Experts recommend approaches for special cases including ocular myasthenia gravis, pregnant patients and children with myasthenia gravis, and more.

Recommendations from neurologists James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN for addressing acute exacerbation in patients with myasthenia gravis.

Two subject matter experts discuss cases where a thymectomy is appropriate for treating patients with myasthenia gravis.

James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN, share insights regarding acetylcholinesterase inhibitors and immunosuppressive therapy as first-line treatments for patients with myasthenia gravis.

Thought leaders offer practical advice on setting therapy goals for patients with myasthenia gravis, with an emphasis on patient inclusion.

Expert panelists discuss misdiagnosis of myasthenia gravis and consider the question of whether this condition should be treated by community physicians.

James F. Howard Jr., MD and Nicholas J. Silvestri MD, FAAN discuss an overview of myasthenia gravis and important tools for diagnosis of myasthenia gravis.